- Home
- BIVI vs NRXS Comparison
BIVI vs NRXS Comparison
Compare BIVI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- NRXS
- Stock Information
- Founded
- BIVI 2013
- NRXS 2011
- Country
- BIVI United States
- NRXS United States
- Employees
- BIVI N/A
- NRXS N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- BIVI Health Care
- NRXS
- Exchange
- BIVI Nasdaq
- NRXS Nasdaq
- Market Cap
- BIVI 15.1M
- NRXS 13.0M
- IPO Year
- BIVI N/A
- NRXS 2023
- Fundamental
- Price
- BIVI $1.08
- NRXS $2.14
- Analyst Decision
- BIVI Strong Buy
- NRXS
- Analyst Count
- BIVI 1
- NRXS 0
- Target Price
- BIVI $30.00
- NRXS N/A
- AVG Volume (30 Days)
- BIVI 821.9K
- NRXS 29.8K
- Earning Date
- BIVI 05-12-2025
- NRXS 05-12-2025
- Dividend Yield
- BIVI N/A
- NRXS N/A
- EPS Growth
- BIVI N/A
- NRXS N/A
- EPS
- BIVI N/A
- NRXS N/A
- Revenue
- BIVI N/A
- NRXS $2,934,945.00
- Revenue This Year
- BIVI N/A
- NRXS $138,883.78
- Revenue Next Year
- BIVI N/A
- NRXS $118.59
- P/E Ratio
- BIVI N/A
- NRXS N/A
- Revenue Growth
- BIVI N/A
- NRXS 27.52
- 52 Week Low
- BIVI $0.62
- NRXS $1.33
- 52 Week High
- BIVI $7.50
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- BIVI 53.44
- NRXS 49.81
- Support Level
- BIVI $1.05
- NRXS $1.94
- Resistance Level
- BIVI $1.29
- NRXS $2.42
- Average True Range (ATR)
- BIVI 0.14
- NRXS 0.26
- MACD
- BIVI 0.02
- NRXS 0.00
- Stochastic Oscillator
- BIVI 52.19
- NRXS 40.99
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).